Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes

PK Chandra, AK Kundu, S Hazari, S Chandra, L Bao… - Molecular Therapy, 2012 - cell.com
Sustained antiviral responses of chronic hepatitis C virus (HCV) infection have improved
recently by the use of direct-acting antiviral agents along with interferon (IFN)-α and ribavirin …

RNA interference with special reference to combating viruses of crustacea

K La Fauce, L Owens - Indian Journal of Virology, 2012 - Springer
RNA interference has evolved from being a nuisance biological phenomenon to a valuable
research tool to determine gene function and as a therapeutic agent. Since pioneering …

Ultradeep sequencing analysis of population dynamics of virus escape mutants in RNAi-mediated resistant plants

F Martínez, G Lafforgue, MJ Morelli… - Molecular Biology …, 2012 - academic.oup.com
Plant artificial micro-RNAs (amiRs) have been engineered to target viral genomes and
induce their degradation. However, the exceptional evolutionary plasticity of RNA viruses …

Luria-Delbrück Estimation of Turnip Mosaic Virus Mutation Rate In Vivo

F de la Iglesia, F Martínez, J Hillung, JM Cuevas… - Journal of …, 2012 - Am Soc Microbiol
ABSTRACT A potential drawback of recent antiviral therapies based on the transgenic
expression of artificial microRNAs is the ease with which viruses may generate escape …

Biodistribution of polymer hydrogel capsules for the delivery of therapeutics

TM Hinton, P Monaghan, D Green, SAA Kooijmans… - Acta Biomaterialia, 2012 - Elsevier
A key phase in the development of intelligently designed nanoparticle delivery vehicles for
new therapeutic agents is to gain an understanding of their interaction with tissues and cells …

RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control

CL Holz, E Albina, C Minet, R Lancelot… - Journal of …, 2012 - Am Soc Microbiol
Viruses are serious threats to human and animal health. Vaccines can prevent viral
diseases, but few antiviral treatments are available to control evolving infections. Among …

In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy

H Lavender, K Brady, F Burden… - Antimicrobial agents …, 2012 - Am Soc Microbiol
ABSTRACT PF-05095808 is a novel biological agent for chronic hepatitis C virus (HCV)
therapy. It comprises a recombinant adeno-associated virus (AAV) DNA vector packaged …

All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution

D Grimm - Molecular Therapy, 2012 - cell.com
Roughly two decades after its discovery and cloning, hepatitis C virus (HCV)—a pathogen
infecting up to 180 million people worldwide and capable of causing severe liver disease …

Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics

A Sindhu, P Arora, A Chaudhury - Molecular biotechnology, 2012 - Springer
A novel laboratory revolution for disease therapy, the RNA interference (RNAi) technology,
has adopted a new era of molecular research as the next generation “Gene-targeted …

Intracellular nucleic acid interactions facilitated by quantum dots: conceptualizing theranostics

L Chong, CH Vannoy, MO Noor, UJ Krull - Therapeutic Delivery, 2012 - Future Science
The concept of theranostics arises from the unification of both diagnostic and therapeutic
applications into a single package. The implementation of nanoparticles, such as …